Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual ... the news and media division of Thomson Reuters, is the ...

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...

However, recent news represents a setback for Novavax's combined vaccine candidate. The U.S. Food and Drug Administration (FDA) ordered a temporary halt to the program and to the company's stand ...

Novavax Inc. closed $15.40 short of its 52-week high ($23.86), which the company achieved on June 6th. Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated ...

The submission is in line with guidance from EMA and the World Health Organization to target the JN.1 lineage this fall.1,2 Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based ...